(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...
Stats | |
---|---|
今日成交量 | 38 279.00 |
平均成交量 | 308 895 |
市值 | 8.27M |
EPS | $-0.175 ( 2023-06-29 ) |
下一个收益日期 | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0.00100 (6.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-17 | Ji Henry | Buy | 19 500 | Common Stock |
2023-03-17 | Ji Henry | Sell | 195 | Put Option (obligation to buy) |
2021-12-31 | Janda Kim | Buy | 0 | |
2022-12-21 | Ji Henry | Buy | 300 | Common Stock |
2022-12-02 | Ji Henry | Buy | 200 | Common Stock |
INSIDER POWER |
---|
99.97 |
Last 96 transactions |
Buy: 40 331 586 | Sell: 980 682 |
Sorrento Therapeutics Inc 相关性
10 最负相关 | |
---|---|
CBAY | -0.967 |
IVCB | -0.952 |
TZPSU | -0.941 |
BCSA | -0.937 |
FUSN | -0.936 |
TZPS | -0.934 |
EBACU | -0.932 |
PFSW | -0.929 |
SWAV | -0.927 |
PAYS | -0.923 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sorrento Therapeutics Inc 财务报表
Annual | 2022 |
营收: | $62.84M |
毛利润: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2022 |
营收: | $62.84M |
毛利润: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2021 |
营收: | $52.90M |
毛利润: | $39.87M (75.37 %) |
EPS: | $-1.450 |
FY | 2020 |
营收: | $39.99M |
毛利润: | $30.05M (75.14 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
Sorrento Therapeutics Inc
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。